Patent ductus arteriosus in preterm neonates

Area of Science:

• Neonatology
• Pediatric Cardiology
• Perinatology

Background:

• Patent ductus arteriosus (PDA) is a common complication in premature neonates, particularly those with respiratory distress syndrome.
• Failure of the ductus arteriosus to close postnatally leads to a left-to-right shunt, causing pulmonary circulation overload.
• Early indicators of PDA include respiratory status deterioration in ventilated neonates and unexplained metabolic acidosis.

Purpose of the Study:

• To outline the medical management of PDA in preterm neonates.
• To highlight the importance of early detection and intervention for PDA.
• To provide guidance on the use of indomethacin and fluid restriction in PDA management.

Main Methods:

• Review of current guidelines and protocols for PDA management.
• Discussion of clinical indicators for early PDA diagnosis.
• Emphasis on pharmacological (indomethacin) and non-pharmacological (fluid restriction) therapeutic strategies.

Main Results:

• Indomethacin remains the primary medical treatment for PDA in preterm infants.
• Restricted fluid therapy may aid in PDA prevention.
• PDA in term neonates necessitates investigation for congenital heart disease.

Conclusions:

• Prompt recognition and management of PDA are vital for improving outcomes in preterm neonates.
• Indomethacin administration protocols should be followed for effective medical treatment.
• Further investigation is warranted for PDA in term infants to exclude underlying cardiac anomalies.